Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Plasmid for silencing cytokine signal inhibitory factor 1 and expressing high mobility group B1 protein and tumor associated antigen and preparation method thereof

A technology for tumor-associated antigens and cytokines, which is applied in the field of plasmids that silence cytokine signal inhibitory factor 1 and express high-mobility group box B1 and tumor-associated antigens and their preparations, which can solve the problems of not exerting biological effects and achieve Stable and efficient transfection, high-efficiency immune response, and no side effects

Inactive Publication Date: 2011-11-09
TIANJIN MEDICAL UNIV CANCER HOSPITAL
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A box protein can replace full-length HMGB1 and bind to the corresponding receptor, but does not exert biological effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Plasmid for silencing cytokine signal inhibitory factor 1 and expressing high mobility group B1 protein and tumor associated antigen and preparation method thereof
  • Plasmid for silencing cytokine signal inhibitory factor 1 and expressing high mobility group B1 protein and tumor associated antigen and preparation method thereof
  • Plasmid for silencing cytokine signal inhibitory factor 1 and expressing high mobility group B1 protein and tumor associated antigen and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0048] The present invention will be described in detail below in conjunction with the accompanying drawings and embodiments.

[0049] The present invention simultaneously realizes the inhibition of DCs antigen presentation negative regulator SOCS1 through H1 and CMV double promoters, the activation of TLRs and the loading of DCs with tumor antigens, and detects its antigen presentation ability and activation effect on T cells by transfecting DCs in vitro , becoming a new and effective way to eliminate host-level self-tolerance, thereby inducing a more effective anti-tumor immune response.

[0050] In the constructed plasmid, the shRNA of SOCS1 was controlled by the human U6 RNA promoter, while the sequence encoding NY-ESO-1 and MAGE3 fusion protein was controlled by the CMV promoter. In this fusion protein, NY-ESO-1 is its full-length coding sequence, and MAGE-3 selects its HLA-A0201 (the HLA allele with the highest expression rate in Asian population) epitope p271-279 coding...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a plasmid for silencing cytokine signal inhibitory factor 1 and expressing high mobility group B1 protein and tumor associated antigen and a preparation method thereof, which belongs to genetic engineering technology. According to the invention, based on a gene recombination method, a cytokine signal inhibitory factor 1 small interfering RNA fragment shSOCS1, a fusion genecoding sequence of NY-ESO-1and MAGE3, and a coding sequence of HMGB1 are connected in the same vector of pIRES-EGFP; respective expression is guaranteed to be correct; and a plasmid coexpressing shSOCS1, HMGB1 and tumor associated antigen is constructed. A new-generation dendritic cell vaccine prepared by the plasmid of the invention can induce high-efficiency immune response of CTL cells with almost no side effects, and can become safe and effective immunotherapy.

Description

technical background [0001] Suppressor of cytokine signaling 1 (SOCS1) is a newly discovered inhibitor of antigen presentation, which has been confirmed to play a key role in maintaining self-tolerance and limiting anti-tumor immunity. SOCS1 is a key negative regulator of the signaling of several proinflammatory cytokines in T cells and antigen-presenting cells, including IFN-γ, IL-2, IL-6, IL-7, IL-12, IL -15 etc. As a feedback mechanism, SOCS1 is induced after proinflammatory response stimulation, which can act as a false substrate to prevent the binding of JAK and STAT, and at the same time increase the ubiquitination and degradation of JAK. In addition, SOCS1 can also inhibit NF-κB signaling pathway to negatively regulate Toll-like receptors (Toll-like receptors, TLRs) signaling. [0002] The latest studies have confirmed that silencing SOCS1 can enhance the immune stimulation ability and duration of dendritic cells (DCs), thereby overcoming host-level self-tolerance and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/63C12N15/66
Inventor 任秀宝魏枫
Owner TIANJIN MEDICAL UNIV CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com